Last updated: August 18, 2026

Examiner: GURLEY, JAMI MICHELLE

Tech Center 1600 • Art Units: 1647 1675

This examiner grants 54% of resolved cases

Performance Statistics

54.2%

Allow Rate

-5.8% vs TC avg

Total Applications

+14.3%

Interview Lift

1327

Avg Prosecution Days

Based on 24 resolved cases, 2023–2026

4.8%

§101 Eligibility

15.7%

§102 Novelty

34.8%

§103 Obviousness

27.6%

§112 Clarity

App #	Title	Status	Assignee
18258397	IL-2 MUTEINS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES	Non-Final OA	MERCK SHARP & DOHME LLC
18253571	METHODS AND COMPOSITIONS COMPRISING MHC CLASS PEPTIDES	Non-Final OA	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
17794917	LIGAND-MEDIATED DELIVERY OF THERAPEUTIC PROTEINS AND THE USES THEREOF	Non-Final OA	Purdue Research Foundation
17632869	DUAL BISPECIFIC ANTIBODY COMPOUNDS AND USES THEREOF	Final Rejection	CITY OF HOPE
18269203	IMMUNOCYTOKINES AND USES THEREOF	Non-Final OA	Immunowake Inc.

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.